- Home
- IOBT
IOBT
IO Biotech Inc.
as 01-17-2025 4:00pm EST
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
| Founded: | 2014 | Country: | Denmark |
| Employees: | N/A | City: | COPENHAGEN |
| Market Cap: | 56.7M | IPO Year: | 2021 |
| Target Price: | $9.33 | AVG Volume (30 days): | 203.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $1.89 | Next Earning Date: | 03-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of IO Biotech Inc. (IOBT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zocca Mai-Britt | IOBT | Chief Executive Officer | Dec 23 '24 | Buy | $0.81 | 12,500 | $10,120.00 | 49,891 | |
| Smith Devin Whittemore | IOBT | General Counsel | Dec 23 '24 | Buy | $0.81 | 12,000 | $9,720.00 | 16,938 | |
| Ahmad Qasim Iftikhar | IOBT | Chief Medical Officer | Dec 23 '24 | Buy | $0.85 | 31,350 | $26,553.45 | 31,350 | |
| Sullivan Amy | IOBT | Chief Financial Officer | Dec 23 '24 | Buy | $0.83 | 10,250 | $8,482.90 | 84,632 |
Latest IO Biotech Inc. News
IOBT Breaking Stock News: Dive into IOBT Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
9 days ago
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
MT Newswires
9 days ago
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
GlobeNewswire
10 days ago
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
GlobeNewswire
a month ago
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank
GlobeNewswire
2 months ago
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
2 months ago
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire
2 months ago
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
Simply Wall St.
3 months ago
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation
Compare IOBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOBT IO Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.